|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Falzarano SM and Magi-Galluzzi C: ERG
protein expression as a biomarker of prostate cancer. Biomark Med.
7:851–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Helgeson BE, Tomlins SA, Shah N, Laxman B,
Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, et
al: Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions
in prostate cancer. Cancer Res. 68:73–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tomlins SA, Laxman B, Varambally S, Cao X,
Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al:
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia.
10:177–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klezovitch O, Risk M, Coleman I, Lucas JM,
Null M, True LD, Nelson PS and Vasioukhin V: A causal role for ERG
in neoplastic transformation of prostate epithelium. Proc Natl Acad
Sci USA. 105:2105–2110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian TV, Tomavo N, Huot L, Flourens A,
Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y and
Duterque-Coquillaud M: Identification of novel TMPRSS2:ERG
mechanisms in prostate cancer metastasis: Involvement of MMP9 and
PLXNA2. Oncogene. 33:2204–2214. 2014. View Article : Google Scholar
|
|
8
|
Shao L, Zhou Z, Cai Y, Castro P, Dakhov O,
Shi P, Bai Y, Ji H, Shen W and Wang J: Celastrol suppresses tumor
cell growth through targeting an AR-ERG-NF-kB pathway in
TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One.
8:e583912013. View Article : Google Scholar
|
|
9
|
Loehrer PJ and Einhorn LH: Drugs five
years later. Cisplatin Ann Intern Med. 100:704–713. 1984.
View Article : Google Scholar
|
|
10
|
Prestayko AW, D'Aoust JC, Issell BF and
Crooke ST: Cisplatin (cis-diamminedichloroplatinum II). Cancer
Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eastman A: The formation, isolation and
characterization of DNA adducts produced by anticancer platinum
complexes. Pharmacol Ther. 34:155–166. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oh WK, Tay MH and Huang J: Is there a role
for platinum chemotherapy in the treatment of patients with
hormone-refractory prostate cancer? Cancer. 109:477–486. 2007.
View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Carver BS, Tran J, Gopalan A, Chen Z,
Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino
PT, et al: Aberrant ERG expression cooperates with loss of PTEN to
promote cancer progression in the prostate. Nat Genet. 41:619–624.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
King JC, Xu J, Wongvipat J, Hieronymus H,
Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et
al: Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation
in prostate oncogenesis. Nat Genet. 41:524–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esgueva R, Perner S, J LaFargue C, Scheble
V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G and
Rubin MA: Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in
a large prostatectomy cohort. Mod Pathol. 23:539–546. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galluzzi L, Aaronson SA, Abrams J, Alnemri
ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren
K, Borner C, et al: Guidelines for the use and interpretation of
assays for monitoring cell death in higher eukaryotes. Cell Death
Differ. 16:1093–1107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Galluzzi L, Vitale I, Abrams JM, Alnemri
ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry
WS, Fulda S, et al: Molecular definitions of cell death
subroutines: Recommendations of the nomenclature committee on cell
death 2012. Cell Death Differ. 19:107–120. 2012. View Article : Google Scholar :
|
|
19
|
Hai TW, Liu F, Coukos WJ and Green MR:
Transcription factor ATF cDNA clones: An extensive family of
leucine zipper proteins able to selectively form DNA-binding
heterodimers. Genes Dev. 3:2083–2090. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Papandreou CN, Daliani DD, Thall PF, Tu
SM, Wang X, Reyes A, Troncoso P and Logothetis CJ: Results of a
phase II study with doxorubicin, etoposide, and cisplatin in
patients with fully char-acterized small-cell carcinoma of the
prostate. J Clin Oncol. 20:3072–3080. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berry W, Friedland D, Fleagle J, Jackson
D, Ilegbodu D, Boehm KA and Asmar L: A phase II study of weekly
paclitaxel/estramustine/carboplatin in hormone-refractory prostate
cancer. Clin Genitourin Cancer. 5:131–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris MH and Thompson CB: The role of the
Bcl-2 family in the regulation of outer mitochondrial membrane
permeability. Cell Death Differ. 7:1182–1191. 2000. View Article : Google Scholar
|
|
24
|
Persengiev SP and Green MR: The role of
ATF/CREB family members in cell growth, survival and apoptosis.
Apoptosis. 8:225–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Persengiev SP, Devireddy LR and Green MR:
Inhibition of apoptosis by ATFx: A novel role for a member of the
ATF/CREB family of mammalian bZIP transcription factors. Genes Dev.
16:1806–1814. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou C, Li Z, Diao H, Yu Y, Zhu W, Dai Y,
Chen FF and Yang J: DNA damage evaluated by gammaH2AX foci
formation by a selective group of chemical/physical stressors.
Mutat Res. 604:8–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao
Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, et al: Mechanistic
rationale for inhibition of poly (ADP-ribose) polymerase in ETS
gene fusion-positive prostate cancer. Cancer Cell. 19:664–678.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han S, Brenner JC, Sabolch A, Jackson W,
Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM
and Feng FY: Targeted radiosensitization of ETS fusion-positive
prostate cancer through PARP1 inhibition. Neoplasia. 15:1207–1217.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haffner MC, Aryee MJ, Toubaji A, Esopi DM,
Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al:
Androgen-induced TOP2B-mediated double-strand breaks and prostate
cancer gene rearrangements. Nat Genet. 42:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
